Igor Gonda is the founder of Respidex LLC – a consulting firm assisting pharmaceutical companies in corporate strategy, including R&D program design, collaborations with patient advocacy groups, regulatory process, intellectual property management, financing and business development.
His current research interests include use of large health-related data bases (“cloud medicine”) to develop better products cheaper and faster; diagnostic methods to detect early signs of evolution of severe respiratory diseases; and management of the respiratory microbiome.
He was previously in various executive roles (Chief Scientific Officer, CEO and President) at Aradigm Corporation – a US company developing inhalation therapies for the prevention and treatment of serious respiratory and systemic diseases, with a focus on products that would optimally meet the needs of patients to help them manage their health.
Igor previously conducted health-related aerosol research and product development at Genentech Inc. (USA) and at universities in the UK, USA and Australia. He was also the CEO and Managing Director of the transdermal company Acrux Ltd in Australia.
He has over 120 US patents and patent applications, and many equivalents in other territories. He published over a hundred papers and is on the editorial board of the Journal of Pharmaceutical Sciences. Igor is a Board member of The Alpha-1 Project – the venture philanthropy arm of the not-for-profit Alpha-1 Foundation searching for cures for the alpha-1 antitrypsin deficiency that leads to emphysema. He is also active in the California Life Sciences Institute to mentor start-up companies on corporate development. He received the British Pharmaceutical Society Astra-Zeneca Industrial Achievement Award and the Thomas T. Mercer Joint Prize of the International Society for Aerosols in Medicine and the American Association for Aerosol Research, for Excellence in Pharmaceutical Aerosols and Inhalable Materials.
Igor graduated in Chemistry and received PhD in Physical Chemistry from the University of Leeds, England.